Search research articles
Contact Us
Filters
Showing results (51-60 of 301) with videos related to
Page
of 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2025
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Walter M Gregory, Thomas J Prior, J Blake Bartlett, et al.
Seminars in Cancer Biology
|
January 8, 2004
HLA-G and lymphoproliferative disorders
Laurence Amiot, Gaëlle Le Friec, Yasmine Sebti, et al.
Annals of Hematology
|
September 1, 2004
Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma
Khalil Kargar Samani, Michel Brazier, Claire Mathiot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients
Maud Brousseau, Xavier Leleu, Jérémie Gerard, et al.
Bulletin Du Cancer
|
May 23, 2008
[Osteonecrosis of the jaw and bisphophonates in oncology]
Thierry Facon, René-Jean Bensadoun, Jean-Louis Blanc, et al.
Haematologica
|
May 30, 2013
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
Meletios A Dimopoulos, Meral Beksac, Lotfi Benboubker, et al.
Blood Cancer Journal
|
March 13, 2021
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Paul G Richardson, Thierry Facon, William I Bensinger, et al.
Advances in Therapy
|
March 18, 2024
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
Brian G M Durie, Shaji K Kumar, Eric M Ammann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2006
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
Jean-Jacques Body, Thierry Facon, Robert E Coleman, et al.
Leukemia & Lymphoma
|
September 24, 2015
Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort
Angela Grelaud, Annie Fourrier-Réglat, Olivier Fitoussi, et al.
Page
of 31
Search research articles
Search
Showing results (51-60 of 301) with videos related to
Sort By:
Page
of 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2025
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Walter M Gregory, Thomas J Prior, J Blake Bartlett, et al.
Seminars in Cancer Biology
|
January 8, 2004
HLA-G and lymphoproliferative disorders
Laurence Amiot, Gaëlle Le Friec, Yasmine Sebti, et al.
Annals of Hematology
|
September 1, 2004
Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma
Khalil Kargar Samani, Michel Brazier, Claire Mathiot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients
Maud Brousseau, Xavier Leleu, Jérémie Gerard, et al.
Bulletin Du Cancer
|
May 23, 2008
[Osteonecrosis of the jaw and bisphophonates in oncology]
Thierry Facon, René-Jean Bensadoun, Jean-Louis Blanc, et al.
Haematologica
|
May 30, 2013
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
Meletios A Dimopoulos, Meral Beksac, Lotfi Benboubker, et al.
Blood Cancer Journal
|
March 13, 2021
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
Paul G Richardson, Thierry Facon, William I Bensinger, et al.
Advances in Therapy
|
March 18, 2024
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
Brian G M Durie, Shaji K Kumar, Eric M Ammann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2006
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
Jean-Jacques Body, Thierry Facon, Robert E Coleman, et al.
Leukemia & Lymphoma
|
September 24, 2015
Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort
Angela Grelaud, Annie Fourrier-Réglat, Olivier Fitoussi, et al.
Page
of 31